{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T05:20:37Z","timestamp":1695792037888},"reference-count":38,"publisher":"Wiley","issue":"s6","license":[{"start":{"date-parts":[[2007,5,31]],"date-time":"2007-05-31T00:00:00Z","timestamp":1180569600000},"content-version":"vor","delay-in-days":1672,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J of Clinical Hypertension"],"published-print":{"date-parts":[[2002,11]]},"abstract":"<jats:p> <jats:italic>Numerous hypertension treatment trials have been reported during the past several years. In comparative studies it has been shown that the use of diuretics or diuretics\/\u03b2 blockers has resulted in a reduction in morbidity\/mortality equivalent to the use of other antihypertensive medications. This is true in both young and elderly patients. In one large 8\u2010year study in diabetics, the use of a \u03b2 blocker\/diuretic combination was shown to be as effective in reducing overall cardiovascular events as an angiotensin\u2010converting enzyme (ACE) inhibitor\/diuretic treatment program. Although most data indicate that the degree of blood pressure lowering accounts for most of the benefit, there are some differences in outcome that may be explained by different mechanisms of drug action. For example: 1) diuretics are more effective in preventing heart failure and overall cardiovascular events than a blockers; 2) an ACE inhibitor\u2010based program is more effective in the elderly in reducing myocardial infarctions and heart failure than a calcium channel blocker\u2010based program; and 3) a nondihydropyridine is more effective in reducing strokes, but less effective in preventing myocardial infarctions or heart failure, than a program based on diuretic therapy. There is also abundant evidence that the use of ACE inhibitors may prevent the occurrence of diabetes in hypertensive individuals and will reduce cardiovascular events in diabetics. Finally, the angiotensin receptor blockers have been shown to slow the progression of renal disease and prevent the occurrence of end\u2010stage renal disease when compared to treatment regimens that do not include an angiotensin receptor blocker or ACE inhibitor. Updated treatment recommendations should include an ACE inhibitor and possibly an angiotensin receptor blocker along with diuretics and \u03b2 blockers as initial therapy. In addition, recommendations for the use of multiple\u2010drug therapy have been reinforced by recent trials. Goal pressures are not readily achieved with monotherapy, especially in high\u2010risk patients.<\/jats:italic> <\/jats:p>","DOI":"10.1111\/j.1524-6175.2002.01700.x","type":"journal-article","created":{"date-parts":[[2007,5,31]],"date-time":"2007-05-31T08:16:07Z","timestamp":1180599367000},"page":"20-31","source":"Crossref","is-referenced-by-count":4,"title":["Update on the Management of Hypertension: Do Recent Clinical Trial Results Indicate a Change in National Recommendations for Therapy?"],"prefix":"10.1111","volume":"4","author":[{"given":"Marvin","family":"Moser","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,12,3]]},"reference":[{"key":"e_1_2_21_2_2","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1001\/archinte.1997.00440420033005","article-title":"Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC VI)","volume":"157","author":"Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC VI)","year":"1997","journal-title":"Arch Intern Med"},{"key":"e_1_2_21_3_2","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1001\/jama.1990.03440130083030","article-title":"The Multiple Risk Factor Intervention Trial Research Group. Mortality rates after 10.5 years for participants in the Multiple Risk Factor Intervention Trial","volume":"263","year":"1990","journal-title":"JAMA"},{"key":"e_1_2_21_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199312233292602"},{"key":"e_1_2_21_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1993.03510060059034"},{"key":"e_1_2_21_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1993.00410020010002"},{"key":"e_1_2_21_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)10327-1"},{"key":"e_1_2_21_8_2","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","article-title":"Tight blood pressure control and risk of macrovascular and micro vascular complications in type 2 diabetes, UKPDS 38","volume":"317","author":"United Kingdom Prospective Diabetes Study Group","year":"1998","journal-title":"BMJ"},{"key":"e_1_2_21_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(95)00606-0"},{"key":"e_1_2_21_10_2","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1001\/archinte.1993.00410050018004","article-title":"Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease","volume":"153","author":"Hebert PR","year":"1993","journal-title":"Arch Intern Med"},{"key":"e_1_2_21_11_2","article-title":"Clinical Management of Hypertension","author":"Moser M","year":"2002","journal-title":"Professional Communications"},{"key":"e_1_2_21_12_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.97.1.48"},{"key":"e_1_2_21_13_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.95.8.2007"},{"key":"e_1_2_21_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-6175.2001.00446.x"},{"issue":"4","key":"e_1_2_21_15_2","first-page":"366","article-title":"Treatment of hypertension in the octogenarian","volume":"2","author":"Moser M","year":"2000","journal-title":"J Clin Hypertens"},{"key":"e_1_2_21_16_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.28.12.2557"},{"key":"e_1_2_21_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06178-5"},{"key":"e_1_2_21_18_2","first-page":"151","article-title":"1999 World Health Organization\u2010International Society of Hypertension. Guidelines for the Management of Hypertension. Guidelines Subcommittee","volume":"17","year":"1999","journal-title":"J Hypertens"},{"key":"e_1_2_21_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/12.9.1034"},{"key":"e_1_2_21_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-199816110-00014"},{"key":"e_1_2_21_21_2","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","article-title":"Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes, UKPDS 38","volume":"317","author":"United Kingdom Prospective Diabetes Study Group","year":"1998","journal-title":"BMJ"},{"key":"e_1_2_21_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)05012-0"},{"key":"e_1_2_21_23_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.15.1967"},{"key":"e_1_2_21_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03306-7"},{"key":"e_1_2_21_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02526-5"},{"key":"e_1_2_21_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02527-7"},{"key":"e_1_2_21_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)04311-6"},{"key":"e_1_2_21_28_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1991.03460240051027"},{"issue":"5","key":"e_1_2_21_29_2","first-page":"301","article-title":"Treating hypertension: calcium channel blockers, diuretics, \u03b2\u2010blockers, ACE inhibitors: is there a difference","volume":"2","author":"Moser M","year":"2000","journal-title":"J Clin Hypertens"},{"key":"e_1_2_21_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011303"},{"key":"e_1_2_21_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011161"},{"issue":"2","key":"e_1_2_21_32_2","first-page":"3","article-title":"Update on the management of hypertension","volume":"6","author":"Giles TD","journal-title":"J Clin Hypertens"},{"key":"e_1_2_21_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08089-3"},{"key":"e_1_2_21_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-6175.2001.00494.x"},{"key":"e_1_2_21_35_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199704173361601"},{"key":"e_1_2_21_36_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.159.13.1403"},{"issue":"2","key":"e_1_2_21_37_2","first-page":"94","article-title":"Combination drug therapy in the management of hypertension: when, with what, and how","volume":"2","author":"Moser M","year":"2000","journal-title":"J Clin Hypertens"},{"key":"e_1_2_21_38_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199812313392701"},{"key":"e_1_2_21_39_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-6175.2001.00457.x"}],"container-title":["The Journal of Clinical Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1524-6175.2002.01700.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1524-6175.2002.01700.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T16:24:05Z","timestamp":1695745445000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1524-6175.2002.01700.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,11]]},"references-count":38,"journal-issue":{"issue":"s6","published-print":{"date-parts":[[2002,11]]}},"alternative-id":["10.1111\/j.1524-6175.2002.01700.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1524-6175.2002.01700.x","archive":["Portico"],"relation":{},"ISSN":["1524-6175","1751-7176"],"issn-type":[{"value":"1524-6175","type":"print"},{"value":"1751-7176","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,11]]}}}